Sarcopenia Market Size and Share 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

(Albany, USA) DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Sarcopenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sarcopenia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sarcopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sarcopenia market.

Request for a Free Sample Report @ Sarcopenia Market Forecast - https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the Key facts of Sarcopenia Market are:
• According to DelveInsight's analysis, sarcopenia market size in the 7MM is expected to grow at a significant CAGR by 2034.
• The total diagnosed prevalent cases of sarcopenia in the 7MM was 27.4 million cases in 2023 and this number is forecasted to climb at a significant CAGR in the research period (2020-2034).
• The Sarcopenia market size in the 7MM reached approximately USD 2,731 million in 2022. Projections indicate a substantial growth during the forecast period.
• Amongst the EU-5 countries, Italy had the highest number of cases followed by Germany with 3,556,282 and 3,194,532 cases respectively. Spain accounted for least number of sarcopenia cases in 2021.
• Japan accounted for 3,104,585 cases sarcopenia in 2021, which accounted for approximately 9% of the total 7MM prevalent cases of sarcopenia.
• According to DelveInsight, males are affected more as compared to females in case of sarcopenia.
• Leading Sarcopenia companies working in the market are OPKO Health (NASDAQ: OPK), TNF Pharmaceuticals (NASDAQ: TNFA), Biophytis (EPA: ALBPS), Biophytis (OTC: BPTSY), Rubedo Life Sciences, Dystrogen Therapeutics, Rejuvenate Biomed, NMD Pharma, Oncocross Therapeutics, Immunoforge and others.
• Sarcopenia therapies expected to launch are Sarconeos (BIO101), MYMD-1, and others.
• In April 2025, TNF Pharmaceuticals, Inc. announced that a platform presentation of the abstract titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGS) Spring Meeting 2025, held April 9-11 in Belfast, Ireland, and online.
• In December 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC study improved sarcopenia and associated clinical outcomes. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for management of cirrhosis.
• In December 2024, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that significant positive topline results from a Phase 2a study of its lead drug candidate MYMD-1® (isomyosamine) was presented at a prestigious international congress of global experts in sarcopenia and related disorders held December 6-8, 2024 in Washington, D.C.
• In October 2024, Rejuvenate Biomed, in collaboration with the University of Leicester, the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC), and Wellcome Leap Inc., has formalized an agreement to conduct a Phase 2 clinical trial targeting sarcopenia associated with chronic obstructive pulmonary disease (COPD).

Sarcopenia Overview
Sarcopenia is a progressive and generalized skeletal muscle disorder associated with aging and various chronic conditions. Sarcopenia leads to the loss of muscle mass, strength, and function, significantly impacting mobility, independence, and overall quality of life in older adults. Sarcopenia is often underdiagnosed but is increasingly recognized as a major public health concern due to the aging global population.
Sarcopenia is caused by multiple factors including hormonal changes, reduced physical activity, inflammation, poor nutrition, and mitochondrial dysfunction. Sarcopenia can be diagnosed through a combination of muscle strength assessments, physical performance tests, and muscle mass measurements using imaging techniques. Sarcopenia is closely linked to increased risks of falls, fractures, hospitalization, and mortality.
Sarcopenia management focuses on resistance training, protein-rich diets, and potential pharmacological interventions. Sarcopenia treatment strategies also explore anabolic agents, myostatin inhibitors, and hormonal therapies under clinical investigation. Sarcopenia awareness and early intervention are essential to prevent disability and improve the functional outcomes in at-risk populations.
Sarcopenia guidelines by international organizations emphasize standardized diagnostic criteria and individualized care plans. Sarcopenia research is rapidly evolving, aiming to discover novel biomarkers and therapies. Sarcopenia, as a distinct medical condition, highlights the need for multidisciplinary approaches to enhance aging-related health outcomes.

Learn more about Sarcopenia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Sarcopenia Prevalence - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Market
The Sarcopenia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sarcopenia market trends by analyzing the impact of current Sarcopenia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Sarcopenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sarcopenia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The sarcopenia market is influenced by various drivers and barriers. Key drivers include the increasing aging population worldwide, leading to a higher prevalence of sarcopenia and a growing demand for effective treatments. Advancements in diagnostic methods have improved early detection, facilitating timely intervention. Additionally, rising awareness among healthcare professionals and patients about age-related muscle loss has heightened the focus on preventive and therapeutic strategies. Economic factors, such as increased healthcare spending and personal healthcare investments, further contribute to market growth.

Conversely, the market faces several barriers. The high cost of treatments, including protein supplements and specialized therapies, can limit accessibility for some patients. Social stigmas associated with aging may deter individuals from seeking treatment. Moreover, the absence of approved pharmacological therapies and reliance on non-drug interventions, such as exercise and dietary modifications, present challenges in managing sarcopenia effectively.

According to DelveInsight, the Sarcopenia market in 7MM is expected to witness a major change in the study period 2020-2034.

Sarcopenia Epidemiology
The Sarcopenia epidemiology section provides insights into the historical and current Sarcopenia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sarcopenia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Sarcopenia Epidemiology @ Sarcopenia Market Dynamics - https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Drugs Uptake
This section focuses on the uptake rate of the potential Sarcopenia drugs recently launched in the Sarcopenia market or expected to be launched in 2020-2034. The analysis covers the Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Sarcopenia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sarcopenia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the Sarcopenia companies and therapies:
• Biophytis: Sarconeos (BIO101)
• Rejuvenate Biomed: RJx-01
• Lipocine Inc: LPCN 1148
• And Many Others

Sarcopenia Pipeline Development Activities
The Sarcopenia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sarcopenia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Sarcopenia pipeline development activities @ Sarcopenia Treatment Market - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Therapeutics Assessment
Major key companies are working proactively in the Sarcopenia Therapeutics market to develop novel therapies which will drive the Sarcopenia treatment markets in the upcoming years are MyMD Pharmaceuticals (NASDAQ: MYMD), Biophytis (EPA: ALBPS), OPKO Health (NASDAQ: OPK), Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others

Learn more about the emerging Sarcopenia therapies & key companies @ Sarcopenia Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Report Key Insights
1. Sarcopenia Patient Population
2. Sarcopenia Market Size and Trends
3. Key Cross Competition in the Sarcopenia Market
4. Sarcopenia Market Dynamics (Key Drivers and Barriers)
5. Sarcopenia Market Opportunities
6. Sarcopenia Therapeutic Approaches
7. Sarcopenia Pipeline Analysis
8. Sarcopenia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Sarcopenia Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Sarcopenia Competitive Intelligence Analysis
4. Sarcopenia Market Overview at a Glance
5. Sarcopenia Disease Background and Overview
6. Sarcopenia Patient Journey
7. Sarcopenia Epidemiology and Patient Population
8. Sarcopenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Sarcopenia Unmet Needs
10. Key Endpoints of Sarcopenia Treatment
11. Sarcopenia Marketed Products
12. Sarcopenia Emerging Therapies
13. Sarcopenia Seven Major Market Analysis
14. Attribute Analysis
15. Sarcopenia Market Outlook (7 major markets)
16. Sarcopenia Access and Reimbursement Overview
17. KOL Views on the Sarcopenia Market
18. Sarcopenia Market Drivers
19. Sarcopenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.